ClinicalTrials.gov
public full text
Public Domain
Biomarkers in Alzheimer's and Parkinson's Diseases for IA
Investigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability and possible DNA damage may correlate with (or predict) the clinical condition of mild cognitive impairment (MCI) and dementia in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Consistency of Serial CSF alpha-Synuclein Seed Amplification Assay Results in the Parkinson's Progression Marker Initiative#150420
- Consistency of Serial CSF alpha-Synuclein Seed Amplification Assay Results in the Parkinson’s Progression Marker Initiative#442460
- Consistency of Serial CSF alpha-Synuclein Seed Amplification Assay Results in the Parkinson’s Progression Marker Initiative#152060
- Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD#837085
- New Biomarkers in Parkinson's Disease#849729
Record · ID 1183810
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive